Nonalcoholic Fatty Liver Disease among Patients with Hypothalamic and Pituitary Dysfunction

Leon A. Adams, Ariel Feldstein, Keith Lindor, Paul Angulo

Research output: Contribution to journalArticle

170 Citations (Scopus)

Abstract

Patients with hypopituitatism develop a phenotype similar to metabolic syndrome with central obesity and diabetes. Similarly, patients with hypothalamic damage may develop central obesity, insulin resistance, and hyperphagia. We sought to examine the clinical associations between hypopituitarism, hypothalamic dysfunction, and nonalcoholic fatty liver disease (NAFLD). A case series of patients seen at our institution with diagnoses of hypopituitarism, hypothalamic obesity, or craniopharyngioma and NAFLD was undertaken. Clinical, laboratory, and liver biopsy features were reviewed. Twenty-one patients were identified. NAFLD was diagnosed 6.4 ± 7.5 years (median 3 years) after the diagnosis of hypothalamic/pituitary dysfunction. Mean gain in body mass index (BMI) between diagnoses of hypothalamic/pituitary disease and NAFLD was 11.3 ± 8.9 kg/m2 at an average yearly rate of 2.2 ± 2.2 kg/m2. The majority of patients developed elevated glucose levels and dyslipidemia by time of diagnosis of NAFLD. Of the 10 patients biopsied, six were cirrhotic, two had nonalcoholic steatohepatitis (NASH) with fibrosis, and two had simple steatosis. Long-term follow-up of 66 ± 33 months (range 12-120) was available for 18 patients. Two required liver transplantation. Six patients died, two from liver related causes. In conclusion, patients with hypothalamic and/or pituitary disease are at risk of excessive weight gain, impaired glucose tolerance, and dyslipidemia with subsequent development of NAFLD. This group has a high prevalence of cirrhosis placing them at risk for liver-related death. The novel evidence that hypothalamic/pituitary dysfunction may be accompanied by progressive NAFLD has important implications for the work-up and management of patients with hypothalamic/pituitary disease.

Original languageEnglish (US)
Pages (from-to)909-914
Number of pages6
JournalHepatology
Volume39
Issue number4
DOIs
StatePublished - Apr 2004
Externally publishedYes

Fingerprint

Hypothalamic Diseases
Pituitary Diseases
Hypopituitarism
Abdominal Obesity
Dyslipidemias
Liver
Fibrosis
Non-alcoholic Fatty Liver Disease
Craniopharyngioma
Hyperphagia
Glucose Intolerance
Liver Transplantation
Weight Gain
Insulin Resistance
Body Mass Index
Obesity
Phenotype
Biopsy
Glucose

ASJC Scopus subject areas

  • Hepatology

Cite this

Nonalcoholic Fatty Liver Disease among Patients with Hypothalamic and Pituitary Dysfunction. / Adams, Leon A.; Feldstein, Ariel; Lindor, Keith; Angulo, Paul.

In: Hepatology, Vol. 39, No. 4, 04.2004, p. 909-914.

Research output: Contribution to journalArticle

Adams, Leon A. ; Feldstein, Ariel ; Lindor, Keith ; Angulo, Paul. / Nonalcoholic Fatty Liver Disease among Patients with Hypothalamic and Pituitary Dysfunction. In: Hepatology. 2004 ; Vol. 39, No. 4. pp. 909-914.
@article{895548a9e5fe42d493f9f789c68365eb,
title = "Nonalcoholic Fatty Liver Disease among Patients with Hypothalamic and Pituitary Dysfunction",
abstract = "Patients with hypopituitatism develop a phenotype similar to metabolic syndrome with central obesity and diabetes. Similarly, patients with hypothalamic damage may develop central obesity, insulin resistance, and hyperphagia. We sought to examine the clinical associations between hypopituitarism, hypothalamic dysfunction, and nonalcoholic fatty liver disease (NAFLD). A case series of patients seen at our institution with diagnoses of hypopituitarism, hypothalamic obesity, or craniopharyngioma and NAFLD was undertaken. Clinical, laboratory, and liver biopsy features were reviewed. Twenty-one patients were identified. NAFLD was diagnosed 6.4 ± 7.5 years (median 3 years) after the diagnosis of hypothalamic/pituitary dysfunction. Mean gain in body mass index (BMI) between diagnoses of hypothalamic/pituitary disease and NAFLD was 11.3 ± 8.9 kg/m2 at an average yearly rate of 2.2 ± 2.2 kg/m2. The majority of patients developed elevated glucose levels and dyslipidemia by time of diagnosis of NAFLD. Of the 10 patients biopsied, six were cirrhotic, two had nonalcoholic steatohepatitis (NASH) with fibrosis, and two had simple steatosis. Long-term follow-up of 66 ± 33 months (range 12-120) was available for 18 patients. Two required liver transplantation. Six patients died, two from liver related causes. In conclusion, patients with hypothalamic and/or pituitary disease are at risk of excessive weight gain, impaired glucose tolerance, and dyslipidemia with subsequent development of NAFLD. This group has a high prevalence of cirrhosis placing them at risk for liver-related death. The novel evidence that hypothalamic/pituitary dysfunction may be accompanied by progressive NAFLD has important implications for the work-up and management of patients with hypothalamic/pituitary disease.",
author = "Adams, {Leon A.} and Ariel Feldstein and Keith Lindor and Paul Angulo",
year = "2004",
month = "4",
doi = "10.1002/hep.20140",
language = "English (US)",
volume = "39",
pages = "909--914",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Nonalcoholic Fatty Liver Disease among Patients with Hypothalamic and Pituitary Dysfunction

AU - Adams, Leon A.

AU - Feldstein, Ariel

AU - Lindor, Keith

AU - Angulo, Paul

PY - 2004/4

Y1 - 2004/4

N2 - Patients with hypopituitatism develop a phenotype similar to metabolic syndrome with central obesity and diabetes. Similarly, patients with hypothalamic damage may develop central obesity, insulin resistance, and hyperphagia. We sought to examine the clinical associations between hypopituitarism, hypothalamic dysfunction, and nonalcoholic fatty liver disease (NAFLD). A case series of patients seen at our institution with diagnoses of hypopituitarism, hypothalamic obesity, or craniopharyngioma and NAFLD was undertaken. Clinical, laboratory, and liver biopsy features were reviewed. Twenty-one patients were identified. NAFLD was diagnosed 6.4 ± 7.5 years (median 3 years) after the diagnosis of hypothalamic/pituitary dysfunction. Mean gain in body mass index (BMI) between diagnoses of hypothalamic/pituitary disease and NAFLD was 11.3 ± 8.9 kg/m2 at an average yearly rate of 2.2 ± 2.2 kg/m2. The majority of patients developed elevated glucose levels and dyslipidemia by time of diagnosis of NAFLD. Of the 10 patients biopsied, six were cirrhotic, two had nonalcoholic steatohepatitis (NASH) with fibrosis, and two had simple steatosis. Long-term follow-up of 66 ± 33 months (range 12-120) was available for 18 patients. Two required liver transplantation. Six patients died, two from liver related causes. In conclusion, patients with hypothalamic and/or pituitary disease are at risk of excessive weight gain, impaired glucose tolerance, and dyslipidemia with subsequent development of NAFLD. This group has a high prevalence of cirrhosis placing them at risk for liver-related death. The novel evidence that hypothalamic/pituitary dysfunction may be accompanied by progressive NAFLD has important implications for the work-up and management of patients with hypothalamic/pituitary disease.

AB - Patients with hypopituitatism develop a phenotype similar to metabolic syndrome with central obesity and diabetes. Similarly, patients with hypothalamic damage may develop central obesity, insulin resistance, and hyperphagia. We sought to examine the clinical associations between hypopituitarism, hypothalamic dysfunction, and nonalcoholic fatty liver disease (NAFLD). A case series of patients seen at our institution with diagnoses of hypopituitarism, hypothalamic obesity, or craniopharyngioma and NAFLD was undertaken. Clinical, laboratory, and liver biopsy features were reviewed. Twenty-one patients were identified. NAFLD was diagnosed 6.4 ± 7.5 years (median 3 years) after the diagnosis of hypothalamic/pituitary dysfunction. Mean gain in body mass index (BMI) between diagnoses of hypothalamic/pituitary disease and NAFLD was 11.3 ± 8.9 kg/m2 at an average yearly rate of 2.2 ± 2.2 kg/m2. The majority of patients developed elevated glucose levels and dyslipidemia by time of diagnosis of NAFLD. Of the 10 patients biopsied, six were cirrhotic, two had nonalcoholic steatohepatitis (NASH) with fibrosis, and two had simple steatosis. Long-term follow-up of 66 ± 33 months (range 12-120) was available for 18 patients. Two required liver transplantation. Six patients died, two from liver related causes. In conclusion, patients with hypothalamic and/or pituitary disease are at risk of excessive weight gain, impaired glucose tolerance, and dyslipidemia with subsequent development of NAFLD. This group has a high prevalence of cirrhosis placing them at risk for liver-related death. The novel evidence that hypothalamic/pituitary dysfunction may be accompanied by progressive NAFLD has important implications for the work-up and management of patients with hypothalamic/pituitary disease.

UR - http://www.scopus.com/inward/record.url?scp=1842480297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842480297&partnerID=8YFLogxK

U2 - 10.1002/hep.20140

DO - 10.1002/hep.20140

M3 - Article

C2 - 15057893

AN - SCOPUS:1842480297

VL - 39

SP - 909

EP - 914

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 4

ER -